

Suggested Reading

1. Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M., Brunner-La Rocca, H. P., Choi, D. J., Chopra, V., Chuquiere-Valenzuela, E., Giannetti, N., Gomez-Mesa, J. E., Janssens, S., Januzzi, J. L., Gonzalez-Juanatey, J. R., Merkely, B., Nicholls, S. J., Perrone, S. V., Piña, I. L., Ponikowski, P., ... EMPEROR-Preserved Trial Investigators (2021). Empagliflozin in Heart Failure with a Preserved Ejection Fraction. *The New England journal of medicine*, 385(16), 1451–1461. <https://doi.org/10.1056/NEJMoa2107038>
2. Ho, J. E., Redfield, M. M., Lewis, G. D., Paulus, W. J., & Lam, C. (2020). Deliberating the Diagnostic Dilemma of Heart Failure With Preserved Ejection Fraction. *Circulation*, 142(18), 1770–1780. <https://doi.org/10.1161/CIRCULATIONAHA.119.041818>
3. McHugh, K., DeVore, A. D., Wu, J., Matsouaka, R. A., Fonarow, G. C., Heidenreich, P. A., Yancy, C. W., Green, J. B., Altman, N., & Hernandez, A. F. (2019). Heart Failure With Preserved Ejection Fraction and Diabetes: JACC State-of-the-Art Review. *Journal of the American College of Cardiology*, 73(5), 602–611. <https://doi.org/10.1016/j.jacc.2018.11.033>
4. Naylor, M., Houstis, N. E., Namasivayam, M., Rouvina, J., Hardin, C., Shah, R. V., Ho, J. E., Malhotra, R., & Lewis, G. D. (2020). Impaired Exercise Tolerance in Heart Failure With Preserved Ejection Fraction: Quantification of Multiorgan System Reserve Capacity. *JACC. Heart failure*, 8(8), 605–617. <https://doi.org/10.1016/j.jchf.2020.03.008>
5. Oghina, S., Bougouin, W., Bézard, M., Kharoubi, M., Komajda, M., Cohen-Solal, A., Mebazaa, A., Damy, T., & Bodez, D. (2021). The Impact of Patients With Cardiac Amyloidosis in HFpEF Trials. *JACC. Heart failure*, 9(3), 169–178. <https://doi.org/10.1016/j.jchf.2020.12.005>
6. Parikh, K. S., Sharma, K., Fiuzat, M., Surks, H. K., George, J. T., Honarpour, N., Depre, C., Desvigne-Nickens, P., Nkulikiyinka, R., Lewis, G. D., Gomberg-Maitland, M., O'Connor, C. M., Stockbridge, N., Califf, R. M., Konstam, M. A., Januzzi, J. L., Jr, Solomon, S. D., Borlaug, B. A., Shah, S. J., Redfield, M. M., ... Felker, G. M. (2018). Heart Failure With Preserved Ejection Fraction Expert Panel Report: Current Controversies and Implications for Clinical Trials. *JACC. Heart failure*, 6(8), 619–632. <https://doi.org/10.1016/j.jchf.2018.06.008>
7. Psotka, M. A., Fiuzat, M., Solomon, S. D., Chauhan, C., Felker, G. M., Butler, J., Teerlink, J. R., Sinha, S. S., O'Connor, C. M., & Konstam, M. A. (2020). Challenges and Potential Improvements to Patient Access to Pharmaceuticals: Examples From Cardiology. *Circulation*, 142(8), 790–798. <https://doi.org/10.1161/CIRCULATIONAHA.119.044976>
8. Vaduganathan, M., Claggett, B. L., Inciardi, R. M., Fonarow, G. C., McMurray, J., & Solomon, S. D. (2022). Estimating the Benefits of Combination Medical Therapy in Heart Failure with Mildly Reduced and Preserved Ejection Fraction. *Circulation*, 10.1161/CIRCULATIONAHA.121.058929. Advance online publication. <https://doi.org/10.1161/CIRCULATIONAHA.121.058929>
9. Vaduganathan, M., Cunningham, J. W., Claggett, B. L., Causland, F. M., Barkoudah, E., Finn, P., Zannad, F., Pfeffer, M. A., Rizkala, A. R., Sabarwal, S., McMurray, J., Solomon, S., & Desai, A. S. (2021). Worsening Heart Failure Episodes Outside a Hospital Setting in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial. *JACC. Heart failure*, 9(5), 374–382. <https://doi.org/10.1016/j.jchf.2021.01.014>